Salk researchers awarded $2.5 million for innovative pancreatic cancer clinical trial
(Salk Institute) Salk Professor and HHMI Investigator Ronald Evans has been awarded $2.5 million by Stand Up 2 Cancer (SU2C) as part of a multi-institution team to conduct clinical studies to open up a new avenue for immunotherapy in the treatment of pancreatic cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Immunotherapy | Pancreas | Pancreatic Cancer | Study